Vaccinex, Inc. VCNX
Set alert
At close · Oct 30
- YTD
- -32.77%
- 1 year
- +5.22%
- Open
- 0.72605
- Prev close
- 0.75
- Mkt cap
- 1.94M
- Vol
- 2
- Avg vol
- 1.20K
- EPS
- -6.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.72605
- High
- 0.72605
- Forward P/E
- -9.36
- Beta
- 0.00
- Short ratio
- 0.60
- Inst. own
- 51.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2024
- 50-d avg
- 3.19
- 200-d avg
- 5.21
- 1y target
- 0.00
News
3 weeks ago globenewswire.com
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer's disease (AD) through…
3 months ago globenewswire.com
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the…
6 months ago globenewswire.com
Vaccinex Reports 2025 Annual Financial Results
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's,…
10 months ago defenseworld.net
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
Valuation and Earnings This table compares Evofem Biosciences and Vaccinex"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share…
1 year ago globenewswire.com
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce…
1 year ago globenewswire.com
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.…
1 year ago globenewswire.com
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Crude Oil Down Over 1%; US Industrial Production Declines In November
Crude Oil Down Over 1%; US Industrial Production Declines In November
-
1 year ago benzinga.com
Dow Dips Over 200 Points; US Retail Sales Top Estimates
Dow Dips Over 200 Points; US Retail Sales Top Estimates
1 year ago globenewswire.com
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage…
1 year ago globenewswire.com
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
1 year ago globenewswire.com
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.…
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
2 years ago globenewswire.com
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company…
2 years ago globenewswire.com
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to…
2 years ago globenewswire.com
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's…
-
2 years ago benzinga.com
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
2 years ago globenewswire.com
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of…
-
2 years ago benzinga.com
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
2 years ago globenewswire.com
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1.
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 years ago globenewswire.com
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
2 years ago globenewswire.com
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to…
2 years ago globenewswire.com
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against…
2 years ago globenewswire.com
Vaccinex, Inc. Announces Reverse Stock Split
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease…
2 years ago globenewswire.com
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating…
-
3 years ago benzinga.com
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near…
-
3 years ago benzinga.com
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
3 years ago benzinga.com
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday.
-
3 years ago benzinga.com
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 112 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 406 companies made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 275 companies made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 201 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 155 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday saw 59 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 56 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 54 companies hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 185 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 345 companies set new 52-week lows.